ORGO
Organogenesis Holdings Inc. NASDAQ Listed Jan 5, 2017$2.43
-0.41%
vs $2.44
Mkt Cap $316.5M
52w Low $2.24
4.4% of range
52w High $6.54
50d MA $2.46
200d MA $3.74
P/E (TTM)
-15.6x
EV/EBITDA
7.3x
P/B
0.7x
Debt/Equity
0.3x
ROE
12.3%
P/FCF
-12.9x
RSI (14)
53.70
ATR (14)
$0.12
Beta
1.48
50d MA
$2.46
200d MA
$3.74
Avg Volume
1.1M
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
85 Dan Road · Canton, MA 02021 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.29 | -0.37 | -27.6% | 2.53 | -19.4% | -6.3% | -1.7% | +3.4% | +12.0% | -4.1% | — |
| Feb 26, 2026 | AMC | 0.21 | 0.31 | +44.2% | 3.70 | +0.8% | -13.2% | -6.5% | -4.3% | +0.0% | +1.0% | — |
| Nov 6, 2025 | AMC | 0.21 | 0.18 | -14.3% | 3.89 | +31.4% | +44.7% | +16.2% | -0.6% | -0.3% | -4.2% | — |
| Aug 7, 2025 | AMC | 0.07 | -0.09 | -228.6% | 4.52 | -10.2% | +0.9% | +1.3% | +5.8% | +0.4% | -4.3% | — |
| May 8, 2025 | AMC | 0.04 | -0.13 | -425.0% | 5.34 | -14.8% | -42.7% | -2.3% | +5.4% | -4.4% | +0.7% | — |
| Feb 27, 2025 | AMC | -0.03 | 0.04 | +233.3% | 3.07 | +32.2% | +102.3% | -12.9% | -6.8% | +19.2% | -6.2% | — |
| Nov 12, 2024 | AMC | 0.01 | 0.09 | +700.4% | 3.45 | +11.6% | +28.4% | -9.5% | -3.7% | +2.1% | +3.6% | — |
| Aug 8, 2024 | AMC | -0.02 | -0.13 | -550.0% | 2.62 | +6.9% | -2.7% | -5.1% | +9.9% | -3.0% | -2.3% | — |
| May 9, 2024 | AMC | -0.02 | -0.02 | -25.0% | 2.28 | +10.1% | +32.9% | -2.3% | -3.7% | +4.2% | -4.0% | — |
| Feb 29, 2024 | AMC | -0.00 | -0.00 | -102.3% | 3.57 | -13.4% | -18.2% | -1.4% | -3.5% | +2.5% | +9.8% | — |
| Nov 9, 2023 | AMC | 0.01 | 0.02 | +300.0% | 1.97 | +18.8% | +11.2% | +5.9% | +8.6% | +0.4% | +0.0% | — |
| Aug 9, 2023 | AMC | 0.03 | 0.04 | +60.0% | 3.39 | -29.8% | -18.9% | +0.7% | -2.5% | -0.7% | -2.6% | — |
| May 10, 2023 | AMC | -0.02 | -0.02 | +0.0% | 2.10 | +11.9% | +37.1% | +7.6% | +2.6% | -4.4% | +4.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28 | Truist | Initiates | Hold | $3 | $2.66 | $2.61 | -1.9% | -1.5% | -1.9% | -8.2% | -5.1% | +4.0% |
| May 8 | BTIG Research | Downgrade | Buy → Neutral | — | $2.53 | $2.04 | -19.4% | -6.3% | -1.7% | +3.4% | +12.0% | -4.1% |
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $2.44 | $2.45 | +0.4% | -0.8% | -5.4% | +0.0% | +3.5% | -2.5% |
| Feb 27 | BTIG | Maintains | Buy → Buy | — | $3.70 | $3.73 | +0.8% | -13.2% | -6.5% | -4.3% | +0.0% | +1.0% |
| Dec 26 | BTIG | Maintains | Buy → Buy | — | $5.87 | $5.70 | -2.9% | -10.1% | -1.3% | -0.6% | +0.0% | -10.4% |
| Dec 15 | BTIG | Maintains | Buy → Buy | — | $4.82 | $4.86 | +0.8% | +0.2% | +7.0% | +1.9% | +9.5% | -2.9% |
| Nov 20 | BTIG | Maintains | Buy → Buy | — | $5.13 | $5.53 | +7.8% | -0.2% | +9.2% | -3.6% | -2.0% | +2.7% |
| Sep 26 | BTIG | Maintains | Buy → Buy | — | $4.68 | $4.68 | +0.0% | -12.4% | +3.9% | -0.9% | +0.5% | -0.2% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.52 | $4.06 | -10.2% | +0.9% | +1.3% | +5.8% | +0.4% | -4.3% |
| Jul 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.49 | $3.90 | -13.1% | -10.2% | +10.9% | -2.5% | +0.2% | +4.3% |
| Mar 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $5.04 | $5.23 | +3.8% | +19.2% | -6.2% | -8.5% | -0.6% | +3.3% |
| Mar 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.57 | $3.09 | -13.4% | -18.2% | -1.4% | -3.5% | +2.5% | +9.8% |
| Dec 27 | BTIG | Maintains | Buy → Buy | — | $3.97 | $4.15 | +4.5% | +6.0% | -0.5% | -2.4% | -0.2% | -9.1% |
| Nov 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.32 | $2.42 | +4.3% | +8.6% | +0.4% | +0.0% | +4.7% | -1.1% |
| Aug 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.75 | $2.67 | -2.9% | +0.7% | -2.5% | -0.7% | -2.6% | -1.1% |
| Aug 10 | BTIG | Maintains | Buy → Buy | — | $3.39 | $2.38 | -29.8% | -18.9% | +0.7% | -2.5% | -0.7% | -2.6% |
| May 24 | BTIG | Upgrade | Neutral → Buy | — | $3.44 | $3.96 | +15.1% | +16.0% | -4.5% | -1.0% | +0.8% | -4.5% |
| Nov 10 | BTIG | Downgrade | Buy → Neutral | — | $3.09 | $2.58 | -16.5% | -14.9% | +9.5% | -1.0% | +0.7% | -5.9% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.40 | $10.68 | -6.3% | -3.4% | +0.3% | +1.2% | -3.3% | +1.8% |
| Aug 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $14.82 | $16.79 | +13.3% | +1.2% | +3.5% | +2.3% | -4.9% | -4.3% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.29 | $17.44 | -9.6% | -7.1% | -4.1% | +3.6% | +5.5% | -9.2% |
| Mar 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.06 | $17.25 | +1.1% | +4.6% | -4.3% | +9.3% | +12.8% | -4.2% |
| Jan 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.49 | $9.75 | +2.7% | +14.4% | -8.0% | +5.8% | -1.5% | +2.5% |
| Jan 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $7.38 | $7.39 | +0.1% | +6.2% | -2.4% | -0.8% | -3.0% | -0.3% |
| Nov 18 | SVB Leerink | Maintains | Outperform → Outperform | — | $4.33 | $4.54 | +4.8% | +8.5% | +4.5% | +3.5% | +1.8% | +0.0% |
| Nov 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.15 | $4.44 | +7.0% | +4.6% | -9.2% | -6.9% | +15.0% | +1.9% |
| Aug 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.85 | $4.10 | +6.5% | +5.2% | +0.5% | +0.0% | +0.2% | +3.7% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.78 | $3.80 | +0.5% | -8.7% | -4.3% | -3.6% | -2.2% | +9.6% |
| Apr 9 | BTIG | Maintains | Buy → Buy | — | $3.22 | $3.48 | +8.1% | +2.8% | +4.5% | -2.9% | -8.6% | -5.5% |
No insider trades available.
8-K
Organogenesis Holdings Inc. -- 8-K Filing
Organogenesis posted record revenue in 2025, indicating strong market demand for its regenerative medicine and advanced wound care products, which should support investor confidence in the company's growth trajectory.
Feb 26
8-K
Organogenesis Holdings Inc. -- 8-K Filing
Organogenesis Holdings appointed a new Chief Accounting Officer, McGuire, with no material related-party transactions disclosed, indicating routine executive staffing changes with no immediate financial impact.
Feb 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 23,277,672 | $121M | Reduced | Dec 2025 |
| 2 | Soleus Capital Management, L.p. | 10,085,951 | $24M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,900,816 | $7M | New | Mar 2026 |
| 4 | D.e. Shaw & Co | 2,297,974 | $5M | Added | Mar 2026 |
| 5 | Assenagon Asset Management S.a. | 1,967,952 | $5M | Reduced | Mar 2026 |
| 6 | Jane Street Group, Llc | 881,687 | $5M | Added | Dec 2025 |
| 7 | Acadian Asset Management Llc | 1,576,645 | $4M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,449,092 | $3M | New | Mar 2026 |
| 9 | Renaissance Technologies Llc | 1,068,538 | $3M | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 881,717 | $2M | Added | Mar 2026 |
| 11 | Sg Americas Securities, Llc | 790,766 | $2M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 554,428 | $1M | Added | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 548,262 | $1M | Reduced | Mar 2026 |
| 14 | Citadel Advisors Llc | 544,235 | $1M | Reduced | Mar 2026 |
| 15 | Los Angeles Capital Management Llc | 491,841 | $1M | Added | Mar 2026 |
| 16 | Flax Pond Capital, Llc | 420,091 | $996K | New | Mar 2026 |
| 17 | Wealth Dimensions Group, Ltd. | 407,965 | $967K | — | Mar 2026 |
| 18 | Fmr Llc | 375,815 | $891K | Added | Mar 2026 |
| 19 | Highmark Wealth Management Llc | 303,029 | $718K | — | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 293,651 | $696K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$316.5M
Enterprise Value
$273.5M
P/E (TTM)
-15.56x
Forward P/E
—
PEG Ratio
-0.01x
P/B
0.71x
P/S
0.62x
P/FCF
-12.94x
EV/EBITDA
7.33x
Shares Out
130.2M
Financials (TTM)
Revenue
$513.6M
Net Income
-$284K
EBITDA
$37.3M
Free Cash Flow
-$24.5M
Op Cash Flow
-$10.3M
EPS Basic
$0.16
EPS Diluted
$-0.16
EPS Forward
$-0.17
Gross Margin
70.4%
Op Margin
2.1%
Net Margin
-0.1%
Balance Sheet
Total Assets
$598.7M
Total Liab.
$164.8M
Total Equity
$433.9M
Cash
$93.7M
LT Debt
$50.7M
Book Value/Sh
$3.42
Debt/Equity
0.31x
Current Ratio
3.62
Quick Ratio
3.32
Returns & Growth
ROE
12.3%
ROA
6.2%
ROIC
8.6%
Rev Growth YoY
+17.0%
EPS Growth YoY
+2353.5%
Price Returns
2W
-0.8%
1M
+9.4%
3M
-19.9%
6M
-50.4%
12M
-6.2%
Technicals
52W High
$6.54
52W Low
$2.24
50d MA
$2.46
200d MA
$3.74
RSI (14)
53.70
ATR (14)
$0.12
Beta
1.48
Avg Volume
1.1M
Dividends
Div Rate
$0.09
Div Yield
3.5%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.00
High
$9.00
Low
$9.00
Median
$9.00
Data updated apr 26, 2026 5:50pm
· Source: financialmodelingprep.com